LONDON (AP) —
In the four decades since the Ebola virus was first identified in
Africa, treatment hasn’t changed much. There are no licensed drugs or
vaccines for the deadly disease. Some are being developed, but none have
been rigorously tested in humans. One experimental treatment, though,
was tried this week in an American aid worker sick with Ebola, according
to the U.S-based group that she works for in Liberia.
There are no licensed drugs or vaccines for the deadly disease. A number
are being developed, but none have been rigorously tested in humans.
(AP Photo/WHO, Christopher Black, File)
Without a
specific treatment, doctors and nurses focus on easing the disease’s
symptoms — fever, headache, vomiting and diarrhea — and on keeping
patients hydrated and comfortable.
The outbreak
in three West African countries — Liberia, Guinea and Sierra Leone — has
sickened more than 1,300 people and more than 700 have died since
March.
WHY ISN’T THERE A TREATMENT BY NOW?
For one thing,
the Ebola virus is hard to work with. The virus doesn’t grow well in
petri dishes and experiments can only be done in the relatively few labs
with the highest security measures.
And while
Ebola is lethal, it’s rare. Outbreaks are unpredictable, giving doctors
few chances to test new treatments.
While the current epidemic is the largest recorded, the number of people sickened by Ebola is small compared to the number killed by other diseases like malaria or dengue.
Much of the funding for Ebola research is from governments that worry about the virus being used in a bioterror attack.
While the current epidemic is the largest recorded, the number of people sickened by Ebola is small compared to the number killed by other diseases like malaria or dengue.
Much of the funding for Ebola research is from governments that worry about the virus being used in a bioterror attack.
“It’s not
economically viable for any company to do this kind of research because
they have stockholders to think about,” said Ben Neuman, a virologist at
the University of Reading in Britain.
WHAT’S IN THE PIPELINE?
There are
about a half dozen Ebola drugs and vaccines in development, several of
which have received funding from the U.S. One drug developed by the U.S.
Army has shown promising results when tested in monkeys.
“We think this
may work because of the animal models but until you do the studies in
humans, you just don’t know,” said Fred Hayden, an infectious diseases
specialist at the University of Virginia, who was not involved in the
research.
While animal studies for vaccine candidates have been encouraging, it’s unclear what dose humans would need.
A Canadian
company, Tekmira, has a $140 million contract with the U.S. government
to develop a Ebola vaccine. An early test of the shot in healthy humans
was stopped recently after the Food and Drug Administration asked for
more safety information.
SHOULD EXPERIMENTAL DRUGS BE USED NOW?
Scientists are
split on whether or not it is a good idea to try experimental drugs and
vaccines before they are approved but the prospect is being informally
discussed.
“Given the
prolonged and unprecedented nature of the epidemic, we need to carefully
consider this,” said Dr. Peter Piot, the co-discoverer of Ebola in 1976
and director of the London School of Hygiene and Tropical Medicine.
The World Health Organization has no plans to facilitate any clinical trials during this outbreak, spokesman Gregory Hartl said.
Other experts
say it’s unethical to use treatments or vaccines that haven’t been
properly tested, and warn the results could be disastrous.
“None of these
drugs or vaccines are ready to be used in humans from a legal point of
view,” said Dr. Heinz Feldmann, chief of virology at the U.S. National
Institute of Allergy and Infectious Diseases.
It would be
impossible to vaccinate or treat everyone in the region but if any tests
do proceed, they would probably be focused on those at highest risk:
health care workers.
The American
woman who got the experimental drug in Liberia worked at a hospital
where Ebola patients were treated. It’s not known what kind of treatment
she received.
If health care
workers are treated, “We will have to explain why some people are
getting the vaccine and others are not,” Feldmann said, adding there are
still vast areas of West African communities suspicious of Western aid
workers and their treatments. “At the moment, it doesn’t even look like
the local population wants it.”
Visit us at CrashCade.com
No comments:
Post a Comment